What's in Bp Consulting, Inc's pipeline?

Bp Consulting, Inc has 10 drugs in our index: 10 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Bp Consulting, Inc's portfolio?

Top competitors by shared drug class: Allergan, Andover Research Eye Institute, Aultman Health Foundation, Bausch & Lomb Incorporated, Chong Kun Dang Pharmaceutical.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bp-consulting-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Bp Consulting, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bp Consulting, Inc pipeline: 10 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

10 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
PEG-400	PEG-400	marketed			Other
New PEG based artificial tear	New PEG based artificial tear	marketed	Artificial tear / Lubricating ophthalmic agent		Ophthalmology
Bromefenac	Bromefenac	marketed			Other
Istalol and Optive	Istalol and Optive	marketed	Beta-blocker (Istalol); Artificial tear/lubricant (Optive)	Beta-adrenergic receptors (Istalol); Non-specific ocular surface lubricant (Optive)	Ophthalmology
Xibrom, and Optive	Xibrom, and Optive	marketed	Topical NSAID (Xibrom); Artificial tear/lubricant (Optive)	COX-1/COX-2 (Xibrom); None—lubricant formulation (Optive)	Ophthalmology
Alphagan	Alphagan	marketed			Other
Xibrom and Pred Forte	Xibrom and Pred Forte	marketed	NSAID (bromfenac) and corticosteroid (prednisolone acetate) combination	COX-1/COX-2 (bromfenac); glucocorticoid receptor (prednisolone acetate)	Ophthalmology
PEG- 400 based artificial tear	PEG- 400 based artificial tear	marketed	Artificial tear / Ocular lubricant		Ophthalmology
Xibrom	Xibrom	marketed		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase	Pain
Blink	Blink	marketed			Other

Therapeutic area mix

Ophthalmology · 5
Other · 4
Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 1 shared drug class
Andover Research Eye Institute · 1 shared drug class
Aultman Health Foundation · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Clinica Oftamologica Zona Sul · 1 shared drug class
Fundação Altino Ventura · 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bp Consulting, Inc:

Cite this brief

Drug Landscape (2026). Bp Consulting, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bp-consulting-inc. Accessed 2026-06-10.